| Date | Title | Description |
| 01.10.2025 | Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers | President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer.
Trump’s agreement with Pfizer included a three-yea... |
| 23.09.2025 | McKesson lifts annual profit forecast on plans to focus on high-margin businesses | McKesson lifts annual profit forecast on plans to focus on high-margin businesses
By Mrinalika Roy and Kamal ChoudhurySeptember 23, 20252:08 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Medic... |
| 09.09.2025 | Shares of this under-the-radar weight-loss drug play could double, says Leerink Partners | - |
| 08.09.2025 | Stocks close at record highs despite job worries, looming inflation reports | All three major indexes closed at record highs Tuesday as investors moved past concerns about the state of the U.S. economy.
The S&P 500 index settled up 0.27% at 6,512.61, while the Nasdaq Composite gained 0.37% to end the day at 21,87... |
| 31.01.2022 | Immutep : to Present at February Investor Conferences | ASX/Media Release
Immutep to Present at February Investor Conferences
SYDNEY, AUSTRALIA - 31 January 2022 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel L... |
| 07.01.2022 | Amylyx Pharmaceuticals Announces Pricing of Upsized Initial Public Offering of Common Stock | Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the pricing of its upsi... |
| 03.01.2022 | Amylyx Pharmaceuticals Announces Launch of Initial Public Offering | Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the launch of its initi... |
| 11.11.2021 | 908 Devices Announces Pricing of Public Offering | 908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the pricing of a public offering of shares of its common stock, with 3,150,000 shares... |
| 11.11.2021 | Mirati Therapeutics Announces Pricing of Public Offering of Common Stock | SAN DIEGO, Nov. 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, today announced the pricing of an underwritten public offering of 3,448,275 shares of its common stock at a price... |
| 10.11.2021 | Mirati Therapeutics Announces Proposed Public Offering of Common Stock | SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) a clinical-stage oncology company, today announced that it intends to offer and sell in an underwritten public offering $500 million of shares of its common st... |
| 09.11.2021 | 908 Devices Announces Launch of Public Offering | 908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the launch of a public offering of shares of its common stock, with 2,750,000 shares ... |
| 02.11.2021 | Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market | Compass Therapeutics, Inc. (the “Company”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it has priced an underwritten public offering to sell 35,715,000... |
| 01.11.2021 | Compass Therapeutics Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market | Compass Therapeutics, Inc. (the “Company”), a clinical stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it intends to offer and sell shares of common stock in an underw... |
| 29.10.2021 | Aura Biosciences Announces Pricing of Initial Public Offering | Aura Biosciences, Inc. (“Aura”), a clinical-stage oncology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the pricing of its initial public offering of 5,400,000 sh... |
| 22.10.2021 | Minerva Surgical : Announces Pricing of Initial Public Offering | SANTA CLARA, Calif., Oct. 21, 2021 /PRNewswire/ -- Minerva Surgical, Inc. (Minerva Surgical), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced the pricing of its initial public offering o... |
| 18.10.2021 | Bicycle Therapeutics : Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares | Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the closing on Friday, October 15, 2... |
| 13.10.2021 | Bicycle Therapeutics : Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares | Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the pricing of an underwritten publi... |
| 12.10.2021 | IsoPlexis : Announces Closing of Public Offering | BRANFORD, Conn., Oct. 12, 2021 /PRNewswire/ -- IsoPlexis Corporation ("IsoPlexis"), a leader in functional single-cell proteomics, today announced the closing of its initial public offering of 8,333,000 shares of common stock at a... |
| 08.10.2021 | IsoPlexis : Announces Pricing of Initial Public Offering | BRANFORD, Conn., Oct. 7, 2021 /PRNewswire/ -- IsoPlexis Corporation ("IsoPlexis"), a leader in functional single-cell proteomics, today announced the pricing of its initial public offering of 8,333,000 shares of common stock at a ... |
| 07.10.2021 | Theseus Pharmaceuticals : Announces Pricing of Initial Public Offering | CAMBRIDGE, Mass., Oct. 6, 2021 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of tr... |
| 23.09.2021 | Synlogic : Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 15,... |
| 22.09.2021 | Synlogic : Announces Proposed Public Offering of Common Stock | CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering... |
| 09.08.2021 | Roger Salazar, Jr. Joins SVB Leerink As Managing Director And Head Of SPACs | SVB Leerink, a leading investment bank specializing in healthcare and life sciences, announced that Roger Salazar, Jr. will join the firm’s investment banking practice leading origination and execution for special purpose acquisition compan... |
| 04.08.2021 | Avidity Biosciences, Inc. : Announces Pricing of Public Offering of Common Stock | LA JOLLA, Calif., Aug. 3, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ... |
| 02.08.2021 | Avidity Biosciences, Inc. : Announces Proposed Public Offering of Common Stock | LA JOLLA, Calif., Aug. 2, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ... |
| 27.07.2021 | Caribou Biosciences : Announces Closing of Upsized Initial Public Offering | Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previously announced initial public offering of 19,000,000 shares of common stock, at a ... |
| 23.07.2021 | Caribou Biosciences : Announces Pricing of Upsized Initial Public Offering | Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering of 19,000,000 shares of common stock at a public offering price of $16.0... |
| 22.07.2021 | Natera : Announces Pricing of Follow-On Offering | AUSTIN, Texas, July 21, 2021 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a pri... |
| 21.07.2021 | Natera : Launches Proposed Follow-On Offering | AUSTIN, Texas, July 20, 2021 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) ("Natera"), a pioneer and global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $350,000,000 of share... |
| 01.07.2021 | Graphite Bio : Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the closing of its previously announced... |
| 25.06.2021 | Theravance Biopharma, Inc. : Announces Pricing of Public Offering of Ordinary Shares | DUBLIN, June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selec... |
| 25.06.2021 | Graphite Bio Announces Pricing of Upsized Initial Public Offering | Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the pricing of its upsized initial public offering of ... |
| 25.06.2021 | Elevation Oncology : Announces Pricing of Initial Public Offering | NEW YORK, June 24, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the... |
| 24.06.2021 | Theravance Biopharma, Inc. : Announces Proposed Public Offering of Ordinary Shares | DUBLIN, June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selec... |
| 22.06.2021 | Ben Brown Joins SVB Leerink as Senior Managing Director to Further Strengthen Healthcare Services Offering | |
| 20.05.2021 | SVB Leerink Hires Anurag Jindal to Expand Biopharma Investment Banking Franchise | |
| 14.05.2021 | AXONICS, INC.
Axonics : reg; Announces Closing of Public Stock Offering and Full Exercise of Underwriters' Option to Purchase Additional Stock | Axonics, Inc. (Nasdaq: AXNX), (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 4... |
| 13.05.2021 | INSMED INCORPORATED
Insmed Incorporated : Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underwriters' Options to Purchase Additional Shares a... | BRIDGEWATER, N.J., May 13, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced registered underwritten public offering (the "Equity Offering") of 11,500,000 shares of its... |
| 12.05.2021 | AXONICS, INC.
Axonics : reg; Announces Upsize and Pricing of Public Offering of Common Stock | Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of... |
| 11.05.2021 | AXONICS, INC.
Axonics : reg; Announces Proposed Public Offering of Common Stock | Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed public offering of ... |
| 11.05.2021 | INSMED INCORPORATED
Insmed Incorporated : Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028 | BRIDGEWATER, N.J., May 11, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 10,000,000 shares of its common stock (the "Shares") at a price to the ... |
| 29.04.2021 | ALDEYRA THERAPEUTICS, INC.
Aldeyra Therapeutics, Inc. : Announces Pricing of $125 Million Public Offering of Common Stock | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the... |
| 27.04.2021 | ALDEYRA THERAPEUTICS, INC.
Aldeyra Therapeutics, Inc. : Announces Proposed $125 Million Public Offering of Common Stock | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced tha... |
| 22.04.2021 | Mission Therapeutics takes part in SVB Leerink Biopharma Private Company Connect event | Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that members of its management will be attending the upcoming SVB Leerink Biopharma Private Co... |
| 22.04.2021 | Mission Therapeutics takes part in SVB Leerink Biopharma Private Company Connect event | Mission Therapeutics takes part in SVB Leerink Biopharma Private Company Connect event
22-04-2021
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announ... |
| 16.04.2021 | SYNLOGIC, INC.
Synlogic : Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., April 16, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 10,... |
| 15.04.2021 | SYNLOGIC, INC.
Synlogic : Announces Proposed Public Offering of Common Stock | CAMBRIDGE, Mass., April 15, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering... |
| 06.04.2021 | SVB Leerink Builds out Structured Finance Practice | |
| 30.03.2021 | EDGEWISE THERAPEUTICS, INC.
Edgewise Therapeutics : Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares | Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced today the closing of its initial public offerin... |
| 26.03.2021 | Edgewise Therapeutics : Announces Pricing of Initial Public Offering | Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced today the pricing of its underwritten initial pu... |
| 26.03.2021 | AVEO PHARMACEUTICALS, INC.
AVEO Pharmaceuticals : Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares | AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes the full exercise by the underwriters of their option to purchase an a... |
| 22.03.2021 | AVEO Announces Proposed Public Offering of Common Stock | BOSTON--(BUSINESS WIRE)--Mar 22, 2021--
AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. In connection with the offering, AVEO intends to grant the u... |
| 01.03.2021 | Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares | EMERYVILLE, Calif.--(BUSINESS WIRE)--Mar 1, 2021--
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today ... |
| 24.02.2021 | Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering | EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb 24, 2021--
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today... |
| 10.08.2020 | Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares | NEW YORK, August 10, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the ... |
| 12.12.2019 | Aurinia Closes $191.7M Public Offering of Common Shares | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today a... |
| 09.12.2019 | Aurinia Prices US$166.7M Public Offering of Common Shares | VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today a... |
| 29.10.2019 | CENTOGENE Announces Proposed Initial Public Offering of Common Shares | October 28, 2019 at 8:53 AM EDT
CAMBRIDGE, Mass. and ROSTOCK, Germany, Oct. 28, 2019 (GLOBE NEWSWIRE) — Centogene B.V. (“Centogene” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical ... |
| 17.09.2019 | Satsuma Pharmaceuticals Completes $90.8M Initial Public Offering | SOUTH SAN FRANCISCO, Calif. — Satsuma Pharmaceuticals, Inc. (“Satsuma” or the “Company”) (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine... |
| 03.09.2019 | Satsuma Pharmaceuticals Inc. Proposes Initial Public Offering of Common Stock | SOUTH SAN FRANCISCO, Calif., Sept. 3, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma”), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, to... |
| - | Castle Biosciences Announces Pricing of Initial Public Offering | FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. announced today the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $16.00 per share. The gross proceeds to Castle Bios... |
| - | Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering | EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb 24, 2021--
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today... |
| - | AVEO Announces Pricing of $48.0 Million Public Offering of Common Stock | BOSTON--(BUSINESS WIRE)--Mar 23, 2021--
AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.00 per shar... |
| - | Here's a rundown of 23 top healthcare banker moves as firms look to staff up with talent in the red-hot space | Samantha Lee/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Healthcare investment bankers are in high demand, and many rainmakers are on the move.
Firms like SVB Leerink, JPMorga... |
